ZYDUS WELLNESS LTD.-$ - 531335 - Closure of Trading Window
Closure of Trading Window.28-12-2021
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation of Newspaper Publication for loss of share certificate.21-12-2021
Zydus gets orphan drug designation from USFDA for antimalarial compound
The orphan drug designation provides eligibility for certain development incentives16-12-2021
Zydus gets nod to conduct Phase II clinical study in patients with CAPS in Australia
The company has received permission to initiate the Phase II clinical study of its NLRP3 inhibitor 'ZYIL1' in patients with CAPS in Australia.13-12-2021
Companies gear up for Omicron version of coronavirus vaccines
Zydus to keep a laboratory product ready based on the new variant01-12-2021
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation of Newspaper Publication of loss of share Certificate.27-11-2021
ZYDUS WELLNESS LTD.-$ - 531335 - Intimation Of Related Party Transaction On Consolidated Basis For The Half Year Ended On September 30, 2021.
Intimation Of Related Party Transaction On Consolidated Basis For The Half Year Ended On September 30, 2021.25-11-2021
ZYDUS WELLNESS LTD.-$ - 531335 - Intimation Of Related Party Transaction On Consolidated Basis For The Half Year Ended On September 30, 2021.
Intimation of Related Party Transaction on Consolidated basis for the half year ended on September 30, 2021.25-11-2021
Zydus gets USFDA nod to market Decitabine injection in the US
Decitabine is used to treat myelodysplastic syndromes, certain types of blood or bone marrow cancer20-11-2021
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor call under Regulation 30 of LODR.15-11-2021